Veru Inc. (VERU)Healthcare | Biotechnology | Miami, United States | NasdaqCM
2.63 USD
-0.12
(-4.197%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.61 -0.02 (-0.018%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:32 a.m. EDT
The investment case here is defined by a stark divergence between the company's precarious fundamentals and the market's aggressive pricing of a turnaround. Fundamentally, the business is deteriorating; the stock has lost over 72% of its value over the last nine years, with the last three annual periods showing consecutive declines. The company is burning cash, reporting negative free cash flow, and carries a negative return on equity. There is no dividend to provide income, and the balance sheet shows significant debt relative to equity. Despite these red flags, the options market is screaming 'bullish,' with traders pouring capital into calls targeting prices nearly ten times the current level. This disconnect suggests that the recent news regarding a supply deal with Novo Nordisk has created a narrative of imminent validation that overrides the historical data. While the statistical forecast models see only a weak downward lean, the speculative flow indicates a high-risk, high-reward bet on a binary event—either the clinical trial success validates the hype and the stock runs to the $24 target, or the fundamentals drag it back down. For now, the momentum is driven entirely by the hope of the Novo deal, not the reality of the financials. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.127947 |
| AutoTheta | 0.137868 |
| AutoETS | 1.365493 |
| MSTL | 1.720892 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.078 |
| Excess Kurtosis | -1.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2014-04-27 |
| Last Dividend Date | 2014-04-27 |
| Debt to Equity Ratio | 9.455 |
| Market Cap | 44,757,088 |
| Forward P/E | -2.66 |
| Beta | -1.20 |
| Website | https://verupharma.com |
As of Aug. 22, 2026, 4:32 a.m. EDT: Speculators are positioning for a significant recovery, evidenced by massive call volume at deep strikes ($1.00) and out-of-the-money targets ($6.00-$11.00) expiring in late 2026 and early 2027. This aggressive buying suggests a belief that the current price is a floor and that a catalyst will drive the stock toward the $24.50 analyst mean. Conversely, put activity is concentrated near the money and slightly out-of-the-money, indicating a hedge against further downside volatility rather than a bearish bet on continued collapse.
| Date | Dividend | Yield % |
|---|---|---|
| 2014-04-28 | 0.7 | 0.932091 |
| 2014-01-27 | 0.7 | 0.877193 |
| 2013-10-28 | 0.7 | 0.705645 |
| 2013-07-29 | 0.7 | 0.767544 |
| 2013-04-29 | 0.7 | 0.904393 |
| 2013-01-28 | 0.6 | 0.774194 |
| 2012-10-31 | 0.6 | 0.857143 |
| 2012-07-30 | 0.6 | 1.039861 |
| 2012-04-30 | 0.6 | 0.998336 |
| 2012-01-30 | 0.5 | 0.959693 |
| 2011-10-31 | 0.5 | 1.098901 |
| 2011-07-29 | 0.5 | 1.084599 |
| 2011-04-29 | 0.5 | 1.057082 |
| 2011-01-27 | 0.5 | 0.924214 |
| 2010-11-01 | 0.5 | 0.909091 |
| 2010-08-02 | 0.5 | 0.990099 |
| 2010-04-21 | 0.5 | 0.740741 |
| 2010-01-27 | 0.5 | 0.924214 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.16463417 |
| Address1 | 2,916 North Miami Avenue |
| Address2 | Suite 1000 |
| All Time High | 245.7 |
| All Time Low | 2.05 |
| Ask | 3.36 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 147,740 |
| Average Daily Volume3 Month | 2,040,601 |
| Average Volume | 2,040,601 |
| Average Volume10Days | 147,740 |
| Beta | -1.196 |
| Bid | 1.93 |
| Bid Size | 2 |
| Book Value | 1.664 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.625 |
| Current Ratio | 4.423 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.73 |
| Day Low | 2.61 |
| Debt To Equity | 9.455 |
| Display Name | Veru |
| Dividend Date | 1,399,420,800 |
| Earnings Call Timestamp End | 1,786,363,200 |
| Earnings Call Timestamp Start | 1,786,363,200 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -27,702,872 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.783 |
| Enterprise Value | 21,702,454 |
| Eps Current Year | -1.195 |
| Eps Forward | -0.985 |
| Eps Trailing Twelve Months | -0.58 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,398,643,200 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.624 |
| Fifty Day Average Change | 0.0009999275 |
| Fifty Day Average Change Percent | 0.00038106993 |
| Fifty Two Week Change Percent | -16.463417 |
| Fifty Two Week High | 7.33 |
| Fifty Two Week High Change | -4.705 |
| Fifty Two Week High Change Percent | -0.64188266 |
| Fifty Two Week Low | 2.05 |
| Fifty Two Week Low Change | 0.57500005 |
| Fifty Two Week Low Change Percent | 0.28048784 |
| Fifty Two Week Range | 2.05 - 7.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 918,743,400,000 |
| Five Year Avg Dividend Yield | 3.71 |
| Float Shares | 15,478,451 |
| Forward Eps | -0.985 |
| Forward P E | -2.6649747 |
| Free Cashflow | -14,444,403 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | -0.115 |
| Fullday Change Percent | -4.19708 |
| Fullday Price | 2.6067 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09219 |
| Held Percent Institutions | 0.19704 |
| Implied Shares Outstanding | 17,050,320 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,398,643,200 |
| Last Dividend Value | 0.7 |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,754,870,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. |
| Long Name | Veru Inc. |
| Market | us_market |
| Market Cap | 44,757,088 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_316215 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -14,109,339 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 46,888,380 |
| Number Of Analyst Opinions | 2 |
| Open | 2.71 |
| Operating Cashflow | -26,042,992 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 3.6 |
| Phone | 305 509 6897 |
| Post Market Change | -0.018300056 |
| Post Market Change Percent | -0.697145 |
| Post Market Price | 2.6067 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 2.74 |
| Price Eps Current Year | -2.1966527 |
| Price Hint | 4 |
| Price To Book | 1.577524 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.181 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.115 |
| Regular Market Change Percent | -4.19708 |
| Regular Market Day High | 2.73 |
| Regular Market Day Low | 2.61 |
| Regular Market Day Range | 2.61 - 2.73 |
| Regular Market Open | 2.71 |
| Regular Market Previous Close | 2.74 |
| Regular Market Price | 2.625 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 91,055 |
| Return On Assets | -0.54026 |
| Return On Equity | -0.64542997 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 17,050,320 |
| Shares Percent Shares Out | 0.082399994 |
| Shares Short | 1,404,196 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,405,459 |
| Short Name | Veru Inc. |
| Short Percent Of Float | 0.0907 |
| Short Ratio | 4.86 |
| Source Interval | 15 |
| State | FL |
| Symbol | VERU |
| Target High Price | 25.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 24.5 |
| Target Median Price | 24.5 |
| Total Cash | 25,737,528 |
| Total Cash Per Share | 1.51 |
| Total Debt | 2,682,892 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.4871 |
| Two Hundred Day Average Change | 0.13790011 |
| Two Hundred Day Average Change Percent | 0.05544615 |
| Type Disp | Equity |
| Volume | 91,055 |
| Website | https://verupharma.com |
| Zip | 33,127 |